Pilot Study: Psilocybin-Assisted Therapy for PTSD
This pilot study is looking at whether psilocybin-assisted therapy can help reduce symptoms of Post-Traumatic Stress Disorder (PTSD). Researchers are testing two approaches: one combines psilocybin with supportive therapy, and the other combines psilocybin with Prolonged Exposure (PE) Therapy, which involves repeatedly facing trauma memories. You might be eligible if you are over 18, identify as a Georgia military veteran, reservist, National Guard member, or active-duty service member, and are seeking treatment for PTSD. The study will measure changes in your PTSD and depression symptoms to see how effective these treatments are. The current status of this study is unclear.
- Study design
- This is an interventional pilot study planning to enroll 150 participants. Participants will be randomized into two different treatment groups to compare the effectiveness of the interventions.
- What's involved
- Participants will receive supportive therapy across preparatory, dosing, and integration sessions. One group will also have 10 sessions of Prolonged Exposure Therapy.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your PTSD and depression symptoms will be measured at 1, 6, and 12 months after the intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Psilocybin-Assisted Therapy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Anna Wise, PhD · PRINCIPAL_INVESTIGATOR · Emory University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in PTSD symptoms based on CAPS-5-R total severity scoreBaseline, 1-month post-intervention
PTSD symptoms will be evaluated using the Revised Clinician-Administered PTSD Scale for DSM-5, that refers to 20 core symptoms as CAPS-5, each rated on a 0-4 severity scale (0 = absent to 4 = extremely severe), combining frequency and intensity. Total possible score range is 0 to 80 with higher scores correlating with worse outcome.
- Change in PCL-5 scoreBaseline, 1, 6 and 12 months post-intervention
The PCL-5 is a 20-item self-report measure of DSM-5 PTSD symptoms. Scores on the PCL range from 0 to 80, with higher scores indicating higher symptom severity, and a cutoff of 33 indicating clinical levels of PTSD symptoms.
- Depression symptoms (PHQ-9)Baseline, 1, 6 and 12 months post-intervention
The PHQ-9 is a 9-item self-report measure of depressive symptoms. A score of 10 or above indicative of a possible major depressive episode, and it provides a measure of severity of these symptoms. Total possible score range is 0-29, higher score correlates with worse outcome.